This article is more than 5 years old. Information may no longer be current.

Visudyne sales continue falling during second quarter

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

VANCOUVER, British Columbia — Worldwide sales of Visudyne totaled $59.3 million during the second quarter, a 37.8% decrease compared with sales for the second quarter 2006, QLT Inc. announced in a press release.

Compared with sales for the second quarter 2006, U.S. sales of Visudyne (verteporfin, Novartis) declined 45.4% to $10.3 million, and international sales declined 35.9% to $49 million, which the company attributes to the approval of alternative age-related macular degeneration treatments.

QLT also reported that revenues for the quarter declined 25% compared with the second quarter 2006 and totaled $35.7 million. Revenues from Visudyne fell 46% to $19 million during the quarter, and QLT's share of profit from Visudyne sales decreased to 24.2% compared with 28.9% for the second quarter 2006, according to the release.